Treatment effects and cost-effectiveness of Autonomy-Enhancing Treatment
Completed
- Conditions
- anxiety disorders (angststoornissen)
- Registration Number
- NL-OMON22151
- Lead Sponsor
- Tilburg University, University of Amsterdam, GGZ inGeest, GGZ Drenthe, Wantveld, Mentaal Beter
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 128
Inclusion Criteria
1. An age between 18 and 65 years;
2. An anxiety disorder according to DSM 5, or DSM-IV-TR with the exception of obsessive-compulsive disorder and post-traumatic stress disorder.
Exclusion Criteria
1. A current psychotic episode;
2. Substance abuse disorder;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Person-centered outcomes and comorbid symptoms: autonomy-connectedness, general psychopathology, depressive symptoms, self-esteem, quality of life.<br /><br>Anxiety symptoms will also be assessed.
- Secondary Outcome Measures
Name Time Method We will also estimate cost-effectiveness in terms of quality adjusted life years (QALYs) and direct and indirect costs associated with health care use and work absence/productivity loss.